Switch theme
Sign up to access all valuation multiples
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
2014
14
Last FY Revenue $0.1M
Last FY EBITDA -$46.2M
$12.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Eyenovia achieved revenue of $0.1M and an EBITDA of -$46.2M.
Eyenovia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eyenovia valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | XXX | -$3.9M | XXX | XXX | XXX |
| Gross Margin | XXX | -6749% | XXX | XXX | XXX |
| EBITDA | XXX | -$46.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -80587% | XXX | XXX | XXX |
| EBIT | XXX | -$37.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | -65457% | XXX | XXX | XXX |
| Net Profit | XXX | -$49.8M | XXX | XXX | XXX |
| Net Margin | XXX | -86889% | XXX | XXX | XXX |
| Net Debt | XXX | $7.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Eyenovia's stock price is $2.
Eyenovia has current market cap of $4.8M, and EV of $12.0M.
See Eyenovia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.0M | $4.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Eyenovia has market cap of $4.8M and EV of $12.0M.
Eyenovia's trades at 209.7x EV/Revenue multiple, and -0.3x EV/EBITDA.
Equity research analysts estimate Eyenovia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eyenovia's P/E ratio is not available.
See valuation multiples for Eyenovia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.8M | XXX | $4.8M | XXX | XXX | XXX |
| EV (current) | $12.0M | XXX | $12.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 209.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEyenovia's revenue per employee in the last FY averaged $4K, while opex per employee averaged $2.4M for the same period.
Eyenovia's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Eyenovia's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Eyenovia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -80587% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $4K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1303% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 25225% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58707% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eyenovia acquired XXX companies to date.
Last acquisition by Eyenovia was XXXXXXXX, XXXXX XXXXX XXXXXX . Eyenovia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Eyenovia founded? | Eyenovia was founded in 2014. |
| Where is Eyenovia headquartered? | Eyenovia is headquartered in United States of America. |
| How many employees does Eyenovia have? | As of today, Eyenovia has 14 employees. |
| Who is the CEO of Eyenovia? | Eyenovia's CEO is Mr. Michael M. Rowe. |
| Is Eyenovia publicy listed? | Yes, Eyenovia is a public company listed on NAS. |
| What is the stock symbol of Eyenovia? | Eyenovia trades under EYEN ticker. |
| When did Eyenovia go public? | Eyenovia went public in 2018. |
| Who are competitors of Eyenovia? | Similar companies to Eyenovia include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Eyenovia? | Eyenovia's current market cap is $4.8M |
| Is Eyenovia profitable? | Yes, Eyenovia is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
